Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Draft scope assessment: unclear. Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. Per RECIST v1.0 criteria: A Complete Response (CR) requires the disappearance of all target lesions. A Partial Response (PR) requires \>=30% decrease in the sum of the longest diameter of target lesions from baseline measurement. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.

All participants meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluated for response.

→

secondary · POSTED

The maximum grade for each adverse event considered to be at least possibly related to treatment will be recorded. Frequency tables will be constructed.

Eighteen of the 19 participants accrued to the study were evaluable for adverse events.

→

secondary · POSTED

Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. A confirmed response is defined as a CR or PR and is documented on 2 consecutive evaluations.

Source null

→

secondary · POSTED

The distribution of response durations will be estimated using the Kaplan-Meier method.

There were no responses.

→

secondary · POSTED

The distribution of progression-free survival times will be estimated using the Kaplan-Meier method.

All participants were evaluable for this endpoint.

→

secondary · POSTED

The distribution of survival times will be estimated using the Kaplan-Meier method.

all participants were evaluable for this endpoint.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-urothelial-carcinoma-imfinzi-92d35647
nct id: NCT00471536
trial label: Pazopanib in Treating Patients With Metastatic Urothelial Cancer
applicability: unclear
applicability note: Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0000
source section id
NCT00471536-om-0000
source outcome index
0
endpoint
Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST])
endpoint definition
Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. Per RECIST v1.0 criteria: A Complete Response (CR) requires the disappearance of all target lesions. A Partial Response (PR) requires \>=30% decrease in the sum of the longest diameter of target lesions from baseline measurement. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.
time origin
Participants will be evaluated every 8 weeks during treatment and up to 1 year after completion of treatment.
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
All participants meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluated for response.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0001
source section id
NCT00471536-om-0001
source outcome index
1
endpoint
Adverse Events Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
endpoint definition
The maximum grade for each adverse event considered to be at least possibly related to treatment will be recorded. Frequency tables will be constructed.
time origin
Every 4 weeks during treatment (maximum duration was 44 weeks)
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Eighteen of the 19 participants accrued to the study were evaluable for adverse events.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0002
source section id
NCT00471536-om-0002
source outcome index
2
endpoint
Confirmed Tumor Response (CR and PR)
endpoint definition
Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. A confirmed response is defined as a CR or PR and is documented on 2 consecutive evaluations.
time origin
Documented on 2 consecutive evaluations 8 weeks apart from the start of the treatment until disease progression/recurrence, assessed up to 1 year
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0003
source section id
NCT00471536-om-0003
source outcome index
3
endpoint
Duration of Response
endpoint definition
The distribution of response durations will be estimated using the Kaplan-Meier method.
time origin
From the time an objective response is first noted to be either a CR or PR to the date progression is documented, assessed up to 1 year
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
There were no responses.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0004
source section id
NCT00471536-om-0004
source outcome index
4
endpoint
Time to Disease Progression
endpoint definition
The distribution of progression-free survival times will be estimated using the Kaplan-Meier method.
time origin
Every 3 months from registration until progressive disease (PD), assessed up to 2 years after registration
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All participants were evaluable for this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0005
source section id
NCT00471536-om-0005
source outcome index
5
endpoint
Survival Time
endpoint definition
The distribution of survival times will be estimated using the Kaplan-Meier method.
time origin
Time from registration until death due to any cause, assessed every 6 months after PD for up to 2 years after registration
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
all participants were evaluable for this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0000
arm key
OG000
arm label
Treatment (Enzyme Inhibitor Therapy)
regimen
Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00471536-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0001
arm key
OG000
arm label
Treatment (Enzyme Inhibitor Therapy)
regimen
Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
analyzed count
18
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00471536-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0002
arm key
OG000
arm label
Treatment (Enzyme Inhibitor Therapy)
regimen
Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00471536-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0003
arm key
OG000
arm label
Treatment (Enzyme Inhibitor Therapy)
regimen
Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
analyzed count
0
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00471536-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0004
arm key
OG000
arm label
Treatment (Enzyme Inhibitor Therapy)
regimen
Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00471536-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
outcome key
om-0005
arm key
OG000
arm label
Treatment (Enzyme Inhibitor Therapy)
regimen
Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00471536-om-0005#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-urothelial-carcinoma-imfinzi-92d35647
nct id
NCT00471536
harm key
EG000
source section id
NCT00471536-ae
event group key
EG000
event group label
Treatment (Enzyme Inhibitor Therapy)
serious affected
3
serious at risk
18
other affected
18
other at risk
18
frequency threshold
0
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice